The clinical utility of genomics in childhood cancer extends beyond targetable mutationsIn Pediatric cancer, whereas long-term survival now approaches 85%, that for patients with relapsed, metastatic or treatment-refractory disease has remained dismal, with virtually no improvement in more than four decades across most disease subtypes. The identification of clinically actionable targets offers promise to patients with ‘hard-to-cure’ cancers by expanding their treatment options. This dataset includes transcriptomic sequencing data from 221 pediatric cancer tumours through the Illumina HiSeq 2500, Illumina NovaSeq 6000, and NextSeq 500 platforms. To request access to this dataset, please click on the hyperlink provided. You will be redirected to the external website to complete your access request. https://ega-archive.org/datasets/EGAD00001009676This collection is openly accessible.The clinical utility of genomics in childhood cancer extends beyond targetable mutations is published on Oncology AI.